21. Rozlytrek


Active ingredient: entrectinib
Diseases: ROS1-positive non-small cell lung cancer and NTRK fusion-positive tumors
Peak sales estimate: $700 million
Approved: Aug. 15, 2019
Company: Roche

The scoop: Rozlytrek entered the market with a bang, snagging green lights in two indications—and putting Bayer on notice. The Roche drug went right up against the German drugmaker’s Vitrakvi in tough-to-treat NTRK fusion-positive tumors, and it did so at a big discount. Its $17,050-per-month list price sits nearly 50% below Vitrakvi’s $32,800-per-month sticker (though the latter drug comes with a pair of access programs, one of which refunds payment when patients don’t respond to therapy within 90 days). For cancer behemoth Roche, the NTRK approval was its first from the FDA that wasn’t linked to a tumor’s particular location in the body. NTRK gene fusions have been found in tumor types including breast, colorectal and thyroid cancers. — Carly Helfand

21. Rozlytrek

Suggested Articles

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.

By redeploying staff, the FDA thinks it can respond to COVID-19-related requests and review protocols within 24 hours of receipt.

The partners leveraged their proximity to the initial outbreak and experience with SARS and MERS to build up a library of neutralizing antibodies.